These new products will also be responsible for the significant growth of total sales for this indication, reaching $3.6B by 2026, resulting in a CAGR (Compound annual growth rate) of 10.6% from 2016–2026.
According to Global Data, throughout the forecast period, the launch of new antibiotics will shape the changes in the market landscape, with current pipeline products expected to cover approximately 73% of the entire market for HAIs caused by Gram-negative bacteria.
The development of new antibiotics focusses on difficult-to-treat bacteria, including CRE and other resistance patterns with a limited number of efficacious treatment options.

Anticipated market size


Anticipated market size
According to Global Data, throughout the forecast period, the launch of new antibiotics will shape the changes in the market landscape, with current pipeline products expected to cover approximately 73% of the entire market for HAIs caused by Gram-negative bacteria.
These new products will also be responsible for the significant growth of total sales for this indication, reaching $3.6B by 2026, resulting in a CAGR (Compound annual growth rate) of 10.6% from 2016–2026.
The development of new antibiotics focusses on difficult-to-treat bacteria, including CRE and other resistance patterns with a limited number of efficacious treatment options.